Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Forms Assay Collaboration with BioLegend

NEW YORK (GenomeWeb News) – PerkinElmer said today that it has struck an assay development and sample testing collaboration with immunological reagents developer BioLegend.

The agreement will enable BioLegend to offer immunoassay development and bioanalytical testing based on PerkinElmer's AlphaLISA assay technology.

The homogenous, bead-based PerkinElmer technology is comprised of quantitative assays with ranges that are broader than standard enzyme-linked immunosorbent assays, and the company said it can save time in lab workflows and can eliminate wash steps that are difficult to automate. PerkinElmer also said that the technology allows for easy integration into automated high-throughput testing systems, such as its JANUS liquid handling system.

"Combining PerkinElmer's technologies with BioLegend's unique immunoassay development capabilities enables scientists to benefit from reduced barriers to discovery such as time or resource constraints," PerkinElmer's Bio-discovery President, Richard Eglen, said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.